Related Experiment Video

Updated: Aug 7, 2026

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

Ambroxol for the prevention of acute upper respiratory disease

K Nobata1, M Fujimura, Y Ishiura

  • 1Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, Kanazawa 920-8641, Japan. k-nobata@yg7.so-net.ne.jp

Clinical and Experimental Medicine
|July 6, 2006
PubMed

Insights

Ambroxol effectively reduced acute upper respiratory disease (AURD) episodes in a clinical study. This mucolytic agent shows promise for preventing common colds and flu, offering a new therapeutic option.

Area of Science:

  • Respiratory Medicine
  • Pharmacology

Background:

  • Acute upper respiratory diseases (AURDs) like the common cold and influenza are prevalent globally.
  • Effective preventive and therapeutic interventions for AURDs remain limited.
  • Mucoactive drugs are often used, but their specific efficacy in preventing AURD requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy of ambroxol, a mucoactive drug, in preventing acute upper respiratory diseases (AURDs).
  • To compare the effectiveness of ambroxol against rebamipide and carbocisteine in reducing AURD frequency.

Main Methods:

  • A randomized controlled trial involving 54 patients divided into three groups: rebamipide, carbocisteine, and ambroxol.
  • The study spanned two six-month periods (summer and winter seasons).
  • Participants received daily doses of rebamipide (300 mg), carbocisteine (1500 mg), or ambroxol (45 mg).

Main Results:

  • Ambroxol treatment significantly decreased the median number of AURD episodes compared to rebamipide (P=0.0049).
  • Carbocisteine did not show a significant reduction in AURD episodes.
  • In a subgroup of unvaccinated patients during winter, ambroxol also significantly reduced AURD episodes (P=0.0028 vs. rebamipide).

Conclusions:

  • Ambroxol demonstrates potential as an effective agent for preventing acute upper respiratory diseases.
  • The findings suggest ambroxol may be a valuable addition to strategies for managing common respiratory infections.

Related Concept Videos

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in various...
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...